Actelion clinical trials

Acquired by Johnson & Johnson, Jun 16, 2017 · source ↗

The registry lists 143 studies whose lead sponsor is Actelion. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 6, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 143. List all 143 → · All Johnson & Johnson studies →

• A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other OptionRecruitingNCT05179876Phase 3

  Sponsor listed in the registry: Actelion · First submitted after Actelion became part of Johnson & Johnson

• Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial HypertensionActive, not recruitingNCT04273945Phase 3

  Sponsor listed in the registry: Actelion · First submitted after Actelion became part of Johnson & Johnson

• A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial HypertensionActive, not recruitingNCT04175600Phase 3

  Sponsor listed in the registry: Actelion · First submitted after Actelion became part of Johnson & Johnson

• A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial HypertensionActive, not recruitingNCT03492177Phase 2

  Sponsor listed in the registry: Actelion · First submitted after Actelion became part of Johnson & Johnson

• Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic SclerosisCompletedNCT02260557Phase 2

  Sponsor listed in the registry: Actelion · First submitted before Actelion became part of Johnson & Johnson

• Pulmonary Artery Remodelling With BosentanCompletedNCT00595049Phase 4

  Sponsor listed in the registry: Actelion · First submitted before Actelion became part of Johnson & Johnson

• Bosentan in Systemic SclerosisCompletedNCT01395732Phase 4

  Sponsor listed in the registry: Actelion · First submitted before Actelion became part of Johnson & Johnson

• Effect of Bosentan in Patients With Metastatic Melanoma Treated With Dacarbazine (DTIC)CompletedNCT01009177Phase 2

  Sponsor listed in the registry: Actelion · First submitted before Actelion became part of Johnson & Johnson

• Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's DiseaseApproved for marketingNCT04914247

  Sponsor listed in the registry: Actelion · First submitted after Actelion became part of Johnson & Johnson

• A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)CompletedNCT02932410Phase 3

  Sponsor listed in the registry: Actelion · First submitted before Actelion became part of Johnson & Johnson

• Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)CompletedNCT03904693Phase 3

  Sponsor listed in the registry: Actelion · First submitted after Actelion became part of Johnson & Johnson

• Selexipag (ACT-293987) in Pulmonary Arterial HypertensionCompletedNCT01106014Phase 3

  Sponsor listed in the registry: Actelion · First submitted before Actelion became part of Johnson & Johnson

• Study of ACT-293987 (NS-304) in Pulmonary Arterial Hypertension (PAH)CompletedNCT00993408Phase 2

  Sponsor listed in the registry: Actelion · First submitted before Actelion became part of Johnson & Johnson

• Comparison of Cadazolid Versus Vancomycin in Children With Clostridium Difficile-associated Diarrhea (CDAD)TerminatedNCT03105479Phase 2/3

  Sponsor listed in the registry: Actelion · First submitted before Actelion became part of Johnson & Johnson

• Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial HypertensionCompletedNCT03187678Phase 3

  Sponsor listed in the registry: Actelion · First submitted before Actelion became part of Johnson & Johnson

• A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary HypertensionTerminatedNCT04271475Phase 3

  Sponsor listed in the registry: Actelion · First submitted after Actelion became part of Johnson & Johnson

• Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple SclerosisCompletedNCT03232073Phase 3

  Sponsor listed in the registry: Actelion · First submitted after Actelion became part of Johnson & Johnson

• Clinical Study to Investigate the Effect of Macitentan on the Concentrations of Rosuvastatin in the Blood of Healthy Male SubjectsCompletedNCT03359291Phase 1

  Sponsor listed in the registry: Actelion · First submitted after Actelion became part of Johnson & Johnson

• Safety and Tolerability Study of Macitentan in Patients With Idiopathic Pulmonary FibrosisWithdrawnNCT01346930Phase 2

  Sponsor listed in the registry: Actelion · First submitted before Actelion became part of Johnson & Johnson

• A Study to Compare the Macitentan-tadalafil Fixed Dose Combination Tablet Relative to the Concomitant Administration of the Reference Tablets of Macitentan and Tadalafil in Healthy SubjectsCompletedNCT03215966Phase 1

  Sponsor listed in the registry: Actelion · First submitted after Actelion became part of Johnson & Johnson

• A Clinical Study to Assess the Effect of Clopidogrel on the Pharmacokinetics of Selexipag and Its Active Metabolite in Healthy Male SubjectsCompletedNCT03496506Phase 1

  Sponsor listed in the registry: Actelion · First submitted after Actelion became part of Johnson & Johnson

• Correlation of LONGterm Wrist ACTigraphy Recorded Physical Performance & 6-minute Walk Distance in Patients With Pulmonary Arterial HypertensionWithdrawnNCT02309463

  Sponsor listed in the registry: Actelion · First submitted before Actelion became part of Johnson & Johnson

• A Study of Selexipag in Participants Who Participated in a Previous Selexipag StudyCompletedNCT04565990Phase 3

  Sponsor listed in the registry: Actelion · First submitted after Actelion became part of Johnson & Johnson

• A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Hypertension Who Were Previously Treated With Macitentan in Clinical Studies.CompletedNCT03422328Phase 3

  Sponsor listed in the registry: Actelion · First submitted after Actelion became part of Johnson & Johnson

• A Study of Macitentan in Children Below 2 Years of AgeWithdrawnNCT05731492Phase 1

  Sponsor listed in the registry: Actelion · First submitted after Actelion became part of Johnson & Johnson

• The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial HypertensionCompletedNCT02558231Phase 3

  Sponsor listed in the registry: Actelion · First submitted before Actelion became part of Johnson & Johnson

• Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT01006265Phase 2

  Sponsor listed in the registry: Actelion · First submitted before Actelion became part of Johnson & Johnson

• A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance ImagingTerminatedNCT04435782Phase 4

  Sponsor listed in the registry: Actelion · First submitted after Actelion became part of Johnson & Johnson

• A Study of Fixed Dose Combination of Macitentan/Tadalafil (10 mg/20 mg) Compared to the Reference Free Combination of Macitentan and Tadalafil in Healthy Adult ParticipantsCompletedNCT05236231Phase 1

  Sponsor listed in the registry: Actelion · First submitted after Actelion became part of Johnson & Johnson

• A Study of Two Different Test Formulations Compared to the Reference Formulation of Macitentan in Healthy Adult ParticipantsCompletedNCT05392530Phase 1

  Sponsor listed in the registry: Actelion · First submitted after Actelion became part of Johnson & Johnson

• A Study of Single and Multiple Doses of Different Formulations of a Prostacyclin Receptor AgonistCompletedNCT05427162Phase 1

  Sponsor listed in the registry: Actelion · First submitted after Actelion became part of Johnson & Johnson

• Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT01093326Phase 2

  Sponsor listed in the registry: Actelion · First submitted before Actelion became part of Johnson & Johnson

• Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple SclerosisCompletedNCT02425644Phase 3

  Sponsor listed in the registry: Actelion · First submitted before Actelion became part of Johnson & Johnson

• A 2-part Study to Investigate the Effect of Macitentan in Healthy Male ParticipantsCompletedNCT04211272Phase 1

  Sponsor listed in the registry: Actelion · First submitted after Actelion became part of Johnson & Johnson

• Clinical Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary HypertensionCompletedNCT02021292Phase 2

  Sponsor listed in the registry: Actelion · First submitted before Actelion became part of Johnson & Johnson

• REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtensionCompletedNCT02310672Phase 4

  Sponsor listed in the registry: Actelion · First submitted before Actelion became part of Johnson & Johnson

• A Study of Two Macitentan Pediatric Formulations in Healthy Adult ParticipantsCompletedNCT04963439Phase 1

  Sponsor listed in the registry: Actelion · First submitted after Actelion became part of Johnson & Johnson

• Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial HypertensionCompletedNCT00667823Phase 3

  Sponsor listed in the registry: Actelion · First submitted before Actelion became part of Johnson & Johnson

• OPsumit USers RegistryCompletedNCT02126943

  Sponsor listed in the registry: Actelion · First submitted before Actelion became part of Johnson & Johnson

• PORtopulmonary Hypertension Treatment wIth maCitentan - a randOmized Clinical TrialCompletedNCT02382016Phase 4

  Sponsor listed in the registry: Actelion · First submitted before Actelion became part of Johnson & Johnson

• A Study for the Identification of Biomarker Signatures for Diagnosis of Pulmonary Hypertension (PH) in Participants at Low or Intermediate Probability of PH Undergoing Cardiac Magnetic Resonance ImagingCompletedNCT04480723Early Phase 1

  Sponsor listed in the registry: Actelion · First submitted after Actelion became part of Johnson & Johnson

• A Study of Two Macitentan Formulations in Healthy Adult ParticipantsCompletedNCT05433675Phase 1

  Sponsor listed in the registry: Actelion · First submitted after Actelion became part of Johnson & Johnson

• Clinical Study to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary HypertensionCompletedNCT02060721Phase 2

  Sponsor listed in the registry: Actelion · First submitted before Actelion became part of Johnson & Johnson

• Retrospective Chart Review of First-time Opsumit® (Macitentan) Users in the United StatesCompletedNCT03197688

  Sponsor listed in the registry: Actelion · First submitted before Actelion became part of Johnson & Johnson

• Extension of the Psychometric Validation Study ORCHESTRA in Patients With PAHCompletedNCT02112487Phase 3

  Sponsor listed in the registry: Actelion · First submitted before Actelion became part of Johnson & Johnson

• A Study of Selexipag in Healthy Male ParticipantCompletedNCT04266756Phase 1

  Sponsor listed in the registry: Actelion · First submitted after Actelion became part of Johnson & Johnson

• Clinical Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device ImplantationCompletedNCT02554903Phase 2

  Sponsor listed in the registry: Actelion · First submitted before Actelion became part of Johnson & Johnson

• Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.CompletedNCT03078907Phase 4

  Sponsor listed in the registry: Actelion · First submitted before Actelion became part of Johnson & Johnson

• A Registry for Patients Taking UptraviCompletedNCT03278002

  Sponsor listed in the registry: Actelion · First submitted after Actelion became part of Johnson & Johnson

• Safety and Efficacy of Miglustat in Chinese NPC PatientsCompletedNCT03910621Phase 4

  Sponsor listed in the registry: Actelion · First submitted after Actelion became part of Johnson & Johnson